搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Verywell Health on MSN
1 年
Cardiac Biomarkers, Cardiac Enzymes, and Heart Disease
Medically reviewed by Jeffrey S. Lander, MDMedically reviewed by Jeffrey S. Lander, MD Cardiac enzymes (the old name), or ...
The Brighterside of News on MSN
6 天
Blood platelet test could save millions of Americans from heart attacks and strokes
Platelets, the small cell fragments circulating in your blood, are essential for healing injuries by clumping together to ...
360dx
11 天
POC High-Sensitivity Troponin Tests Could Reduce ER Overcrowding. Is That Enough for Adoption?
Several firms are bringing high-sensitivity cardiac troponin testing into the ER, although doctors are not yet certain how ...
Medical News Today
15 天
Aristada interactions: Alcohol, medications, and other factors
Aristada is a prescription drug used for schizophrenia. Find out about possible interactions with alcohol, other drugs, ...
Yahoo
5 天
What To Know and Do About Left Upper Quadrant (LUQ) Pain
Pancreas: The body and tail of the pancreas are located in the left upper quadrant, close to the spleen. It produces ...
Mail & Guardian
4 天
Boostaro reviews – Should you buy this blood support capsule?
A 180-day, 100% money-back guarantee is available and applicable to all bottles of the Boostaro supplement. If you are ...
thecardiologyadvisor.com
18 天
Future of CRISPR: Gene Editing Technologies Herald Landmark Clinical Trials
The future of CRISPR involves clinical trials focused on treatment for blood diseases and cancers, cardiovascular disease, ...
20 天
Lilly And EVA Pharma Collaborate To Expand Access To Baricitinib In Low- To Middle-Income ...
Since 2021, EVA Pharma has been working with Lilly to ensure a sustainable supply of life-saving medicines across several ...
6 天
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in ...
DAYBREAK was a Phase 3, multi-center, long-term open-label extension study to evaluate the safety and efficacy of Zeposia (ozanimod) administered orally to patients with relapsing forms of multiple ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈